Notes from the EndoChoice S-1 IPO Filing

EndoChoice went public today on the New York Stock Exchange (NYSE:GI) raising $95 million. This is notable because it’s the first entrepreneur-lead company in Atlanta to go public in many years. Founded in 2008, EndoChoice is a medtech company focused on technologies and products for gastrointestinal conditions with their main innovation being an endoscopic imaging system.

Here are a few notes from the EndoChoice S-1 IPO filing:

• Serves over 2,500 GI departments (pg. 1)
• Fuse® system enables GI specialists to see more than twice the anatomy at any one time compared to standard, forward-viewing colonoscopes and has been clinically demonstrated to detect 69% more pre-cancerous polyps than standard colonoscopes. (pg. 1)
• 15 million colonoscopies per year in the United States (pg. 1)
• Revenues (pg. 2)
  2012 – $34.2 million
  2013 – $50.9 million
  2014 – $61.4 million
• Net losses (pg. 2)
  2012 – $1.2 million
  2013 – $23.9…